Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the Altimmune securities is from December 1, 2023, to April 26, 2024 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by July 5, 2024, to serve as lead plaintiff [1][4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company [2] - The firm was ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [2] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [2] Group 3: Allegations Against Altimmune - The lawsuit alleges that Altimmune made false and misleading statements regarding its lead product candidate, pemvidutide, particularly in relation to its efficacy and tolerability compared to competitors [3] - It is claimed that the results from the MOMENTUM trial were less significant than represented, impacting Altimmune's commercial prospects [3] - The lawsuit asserts that these misrepresentations led to an overstatement of Altimmune's potential for finding a strategic partner for pemvidutide [3]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Altimmune, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, pemvidutide, during a specified class period [1][2]. Group 1 - The class period for the allegations is from December 1, 2023, to April 26, 2024 [1]. - The complaint claims that Altimmune overstated the potential of pemvidutide compared to competing glucagon-like peptide-1 agonists based on the results from the MOMENTUM Trial [1]. - It is alleged that the results of the MOMENTUM Trial were less significant for pemvidutide's clinical and commercial prospects than what was communicated to investors [1]. Group 2 - The lawsuit also contends that Altimmune's public statements were materially false and misleading, impacting the company's perceived prospects for finding a strategic partner for pemvidutide [1]. - Shareholders are encouraged to register for the class action by July 5, 2024, to participate in potential recovery [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. Group 3 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

These stocks might not be small for too much longer.If you go to California's Redwood National Park, you can see the world's tallest tree -- a redwood called Hyperion that's over 380 feet tall. Like every other tree, though, Hyperion started as a small seed. Stocks can be like this, beginning small but growing to a giant size over time. Three Motley Fool contributors think they've found some monster stocks in the making you can buy right now. Here's why they picked Altimmune (ALT -10.00%), Axsome Therapeuti ...

The obesity market has garnered much interest lately, ever since Novo Nordisk (NVO) received FDA approval for its obesity drug Wegovy in 2021. It was only after a couple of years that the market gained a second entrant – Eli Lilly’s (LLY) Zepbound, which received FDA approval last year in November.Lilly and Novo have been registering top- and bottom-line growth, owing to the vastness of the total market size for obesity. The companies even achieved a market cap north of $500 billion. However, these firms ha ...

Core Viewpoint - Investors in Altimmune, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred during the specified class period [1] Group 1: Class Action Details - The class period for the lawsuit is defined as December 1, 2023, to April 26, 2024 [1] - The deadline for potential lead plaintiffs to file is set for July 5, 2024 [1] Group 2: Allegations Against Altimmune - The complaint alleges that Altimmune overstated the potential of its drug pemvidutide compared to competing GLP-1 agonists based on misleading efficacy and tolerability results from the MOMENTUM Trial [2] - It is claimed that the results of the MOMENTUM Trial were less significant for pemvidutide's clinical and commercial prospects than previously communicated to investors [2] - The allegations further state that the company exaggerated its prospects for securing a strategic partner for pemvidutide's development, leading to materially misleading statements about its business and operations [2]

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) and certain officers. The class action, filed in the United States District Court for the District of Maryland, Southern Division, and docketed under 24-cv-01315, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Altimmune securities between December 1, 2023 and Ap ...

NEW YORK, May 15, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "Class Period"), of the important July 5, 2024 lead plaintiff deadline.SO WHAT: If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT TO DO NE ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition p ...

Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Rich Eisenstadt - Chief Financial Officer Vipin Garg - President & Chief Executive Officer Scott Harris - Chief Medical Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Roger Song - Jefferies Alana Lelo - Guggenheim Mayank Mamtani - B. Riley Securities Jon Wolleben - Citizens JMP Operator Good day, ladies and gentlemen and welcome to Altimmune Inc. First Quarter 2024 Financi ...

Financial Performance - Altimmune reported cash, cash equivalents, and short-term investments of $182.1 million as of March 31, 2024[6]. - The net loss for Q1 2024 was $24.4 million, or $0.34 per share, compared to a net loss of $20.1 million, or $0.40 per share, in the same period in 2023[6]. - Interest income for Q1 2024 was $2.4 million, an increase from $1.7 million in Q1 2023, due to higher interest earned on cash equivalents[6]. - Total liabilities decreased to $15.4 million as of March 31, 2024, compared to $16.5 million at the end of 2023[14]. - Total stockholders' equity decreased to $172.9 million as of March 31, 2024, down from $194.1 million at the end of 2023[15]. Research and Development - Research and development expenses increased to $21.5 million for Q1 2024, up from $17.2 million in Q1 2023, with $13.5 million allocated to pemvidutide development[6]. - Enrollment is ongoing in the IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), targeting approximately 190 subjects[5]. - Top line results from the IMPACT trial are expected in Q1 2025, with primary efficacy measures focusing on MASH resolution or fibrosis improvement[5]. - In the MOMENTUM trial, 74.5% of weight loss in pemvidutide-treated subjects came from body fat, indicating effective fat reduction[4]. - The company plans to present a comprehensive data package at the End-of-Phase 2 meeting with the FDA, expected in late Q3 2024[5].